Please ensure Javascript is enabled for purposes of website accessibility

The FDA Can't See the Forest or the Trees

By Brian Orelli, PhD - Updated Apr 5, 2017 at 8:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Forest and Cypress are still waiting, but they've got more data to prove their point.

It's been over a month since Forest Laboratories (NYSE:FRX) and Cypress Bioscience (NASDAQ:CYPB) said that the Food and Drug Administration was indefinitely delaying its decision about whether to approve their fibromyalgia treatment, milnacipran.

The companies certainly wish the FDA would do something, but they're not sitting on their hands, waiting demurely. In true in-your-face fashion, Forest and Cypress released data from a third phase 3 trial, which confirmed the results of the two trials that the FDA is currently reviewing. Of course the companies were nice about it -- no need to piss off the FDA reviewers -- but I can only imagine that the executives were smiling as they issued the press release.

The companies didn't offer much data from the trial -- they're likely saving it for a scientific meeting. Hopefully the FDA won't need it, either; a request for the data could further delay the approval process, which is already nearly two months beyond the PDUFA date.

Forest and Cypress must be annoyed, but they've got company -- Eli Lilly's (NYSE:LLY) prasugrel is currently suffering a delay and CV Therapeutics' (NASDAQ:CVTX) Ranexa recently had to endure a wait. The indefinite delay -- as opposed to the more standard three-month kind -- makes launching milnacipran difficult, to say the least. The drug will enter the market against established players like Eli Lilly's Cymbalta and Pfizer's (NYSE:PFE) Lyrica. How can the companies hit the ground running if they don't know when an approval might be handed down?

I think we're likely to see an eventual approval. Hopefully this latest release of data reminds the FDA that it's got an application gathering dust. I'll join in the company's call: Approve the thing already.

More Foolishness:

 

Pfizer and Eli Lilly are Motley Fool Income Investor selections. Pfizer is also an Inside Value pick and the Fool owns shares of it. CV Therapeutics is a Rule Breakers recommendation. Try any of our Foolish newsletters today, free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool's disclosure policy would like to see a forest full of cypress trees.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$308.08 (2.63%) $7.89
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.11 (3.77%) $1.82
Gilead Palo Alto, Inc. Stock Quote
Gilead Palo Alto, Inc.
CVTX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.